Location Directory

Clinical trials in Columbus, Ohio

This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10859

Shown on this page

Current sort

Institutions in Columbus

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Ohio State University Wexner Medical Center

Live official records

Open in full search

Conditions: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
Interventions: Not listed
Lead sponsor: Accelerated Cure Project for Multiple Sclerosis; Other
Eligibility: Not listed
Enrollment: 3,226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2036
U.S. locations: 10
States / cities: Phoenix, Arizona • Stanford, California • Aurora, Colorado + 7 more

Conditions: Risk Reduction, Breast Cancer
Interventions: Bazedoxifene and Conjugated Estrogens; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years to 64 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Duarte, California • San Francisco, California • Chicago, Illinois + 3 more

Conditions: Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions: Aspirin 81 mg, Aspirin 162 mg; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 14 Years to 35 Years · Female only
Enrollment: 10,742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more

Conditions: Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Tuvusertib, X-Ray Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Augusta, Georgia • Chicago, Illinois • Iowa City, Iowa + 8 more

Conditions: Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions
Interventions: TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 36
States / cities: Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 31 more

Conditions: Pediatric Migraine
Interventions: Rimegepant/BHV3000, Matching placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 2,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 169
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cobimetinib, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • La Jolla, California • Washington D.C., District of Columbia + 13 more

Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 502
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 349 more

Conditions: Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors
Interventions: ziftomenib, imatinib mesylate; Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more

Conditions: Alzheimer Disease
Interventions: KarXT, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 102
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 71 more

Conditions: Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Iadademstat; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 32
States / cities: Irvine, California • Orange, California • Palo Alto, California + 28 more

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 366 Days to 46 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 145
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more

Clinical trials in Columbus, Ohio

Filter and sort this location

Institutions in Columbus

Live official records

Biobank For MS And Other Demyelinating Diseases

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)